Skip to content
TrialScanner

NCT00900614

Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer

Phase 1CompletedAPRELead

Registry record

Lead sponsor
Aprea Therapeutics
Conditions
Hematologic Neoplasms; Prostatic Neoplasms
Primary completion
Oct 2010Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT00900614 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT00900614: Safety Study of APR-246 in... | TrialScanner